Company Overview
Snapshot
Founded in December 2015 by Gilad Litvin and Almog Aley-raz, CorNeat Vision operates with 11–50 employees. The company has raised $18.77 million across 7 funding rounds from 2 investors. In June 2023, the American Food & Drug Administration (FDA) approved its EverPatch, the world’s first non-degradable synthetic tissue for ophthalmic surgery.
Business overview
CorNeat Vision is a medical device company specializing in the development and commercialization of novel, permanent, and tissue-integrating implants. The company's core technology, CorNeat EverMatrix™, is a platform material designed to overcome the foreign body response typically triggered by implants, allowing seamless and permanent integration with live tissue without inflammation. This technology is positioned to replace harvested human and animal tissues used in various surgical procedures. CorNeat Vision operates within the Health Tech & Life Sciences sector, specifically targeting the Pharma & Medical Biotechnology and Biomaterials & Tissue Engineering markets.
Strategic signal
In September 2025, CorNeat Vision announced a significant milestone in its RESEE clinical trial, reaching 50% enrollment for the CorNeat KPro artificial cornea. This trial demonstrated the device's ability to restore perfect 20/20 vision in a patient blinded by Shingles, who was not a candidate for traditional corneal transplantation. This achievement signals strong clinical validation and progress towards FDA 510(k) clearance and CE Marking, indicating the company's potential to address a critical unmet need in ophthalmology and expand its market reach.
Log in to access full profile ›Company Intelligence Q&A
- What was a key regulatory approval CorNeat Vision received?
- In June 2023, the American Food & Drug Administration (FDA) approved CorNeat Vision's EverPatch, the world’s first non-degradable synthetic tissue for ophthalmic surgery. This product is designed to replace donor tissue and will be launched in leading ophthalmic centers in the US.
- What is the status of the RESEE clinical trial for the CorNeat KPro?
- In September 2025, CorNeat Vision announced that its RESEE clinical trial for the CorNeat KPro artificial cornea reached 50% enrollment. The trial successfully restored 20/20 vision in a patient with corneal scarring from Shingles, who was previously unsuitable for traditional corneal transplantation.
- Which organizations are supporting the CorNeat KPro project?
- The CorNeat KPro project is supported by the European Innovation Council and a U.S. Army Project Award, as noted in September 2025.
- When did CorNeat Vision raise funding from the Guangzhou Sino-Israel Biotech Investment Fund?
- In August 2021, CorNeat Vision raised funding from the Guangzhou Sino-Israel Biotech Investment Fund (GIBF). These funds were allocated to its Chinese subsidiary to expand activities in the Chinese market, including clinical trials, manufacturing, and marketing.
- What was a significant early clinical achievement for CorNeat Vision?
- In January 2021, CorNeat Vision successfully implanted its KPro artificial cornea into a patient, Jamal Furani, who had lost his vision due to corneal disease. This surgery restored his vision and marked the first step in a multinational clinical trial aimed at achieving CE Mark, FDA clearance, and China NMPA approval.